FINWIRES · TerminalLIVE
FINWIRES

Research Alert: Cisco Systems Delivers Record Results Fueled By Ai And Networking Refresh

By

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:

CSCO delivered exceptional Q3 FY 26 results with revenue surging 12% Y/Y to a record $15.8B and non-GAAP EPS of $1.06 representing 10% growth, significantly exceeding guidance across all metrics. The standout Networking segment posted 25% Y/Y growth to $8.8B driven by AI infrastructure investments, while product orders accelerated 35% Y/Y with networking orders up over 50%. However, Security remained flat at $2.0B, marking concerning deceleration from recent double-digit growth rates. Management raised AI infrastructure expectations to $9B orders and $4B revenue for FY 26, up from $5B and $3B, respectively, with Q4 guidance of $16.7B-$16.9B revenue and $1.16-$1.18 EPS. We believe CSCO's increasingly prominent role in AI-driven infrastructure transformation provides solid foundation for continued growth, though we note the uneven demand across segments with Security weakness highlighting competitive intensity in cybersecurity markets.

Related Articles

Research

Research Alert: CFRA Keeps Sell Opinion On Shares Of Murphy Oil Corporation

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our 12-month target price by $2 to $31, reflecting a combination of our DCF and relative valuation models. On a relative basis, we apply a 4.0x multiple of enterprise value to projected 2027 EBITDA, slightly below peers, but we think a discounted multiple is reasonable, as we see a narrower surplus of operating cash flow to handle capex requirements than do most peers. This approach yields a value of $26 per share. Meanwhile, our DCF model, using medium-term free cash flow growth of 4% per year, terminal growth of 2%, discounted at a WACC of 6.1%, yields intrinsic value of $37 per share. We lift our 2026 EPS estimate by $2.56 to $3.89 but lower 2027's by $0.18 to $1.85. We see possible risk in 2027 from a commodity price downturn, which could crimp growth in capex spending, or growth in returns to shareholders. Our estimates for 2027 are a fair bit lower than consensus, which has less to do with company-specific factors, and more to do with our take on the macroeconomic view of crude oil prices.

$MUR
Research

Research Alert: Dox Posts In-line Quarter, Modest Backlog Growth; Maintains Fy 26 Guidance

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:DOX's Mar-Q results slightly exceeded expectations, with sales of $1.172B (+3.9% Y/Y) and non-GAAP EPS of $1.78 beating consensus views of $1.166B and $1.76, respectively. Constant currency sales growth again decelerated, coming in at 2.2% from the prior quarter's 3.5% rate, with managed services (65% of sales) slowing to 1.6% growth from 2.3% growth in Q1. Management narrowed its FY 26 guidance ranges, with sales growth now expected at 2.6%-4.6% (vs. prior 1.5%-5.5%) and EPS growth expected at 5%-7% (vs. prior 4%-8%). 12-month backlog grew 2.6% Y/Y to $4.28B, offering strong support for the company's modest sales growth outlook with minimal reliance on shorter-term discretionary work (which has been under pressure amid the uncertain macro environment). CFO Tamar Rapaport-Dagin will be leaving the company, with Tal Rozenfeld (Head of Finance) taking over effective June 2026, though we expect no material operating impact from the change.

$DOX
Research

Research Alert: CFRA Maintains Hold Rating On Shares Of Unitedhealth Group

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our 12-month price target to $440 from $385, 24x our 2026 EPS estimate (up $0.11 to $18.36; 2027 estimate up $0.64 to $20.76), a premium to UNH's 10-year historical forward average of 19.4x. Our target multiple is above most peers to reflect strong FCF generation, balance sheet strength, scale advantages, and a diversified business model across health insurance, pharmacy benefit management, health care technology and analytics, and outpatient facility networks. We are upgrading our 12-month fundamental outlook for the managed health care sub-industry to neutral from negative, with UNH and peers taking steps to improve profitability via increased medical premiums, strategic portfolio shifts/exits, and heightened focus on cost control within an elevated medical cost landscape. We anticipate that these actions may improve margins and profitability looking ahead to 2027-2028 and think valuations could gradually improve.

$UNH